enGene (NASDAQ:ENGN) Issues Quarterly Earnings Results

enGene (NASDAQ:ENGN) issued its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.06, Zacks reports.

enGene Price Performance

ENGN stock opened at $5.83 on Friday. The firm has a market cap of $257.78 million, a P/E ratio of -10.05 and a beta of -0.78. The firm’s fifty day moving average is $8.13 and its 200 day moving average is $7.80. enGene has a 52 week low of $4.42 and a 52 week high of $18.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52.

Insider Buying and Selling at enGene

In other enGene news, major shareholder Growth Opportunities F. Forbion bought 41,639 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average cost of $5.97 per share, with a total value of $248,584.83. Following the completion of the purchase, the insider now directly owns 2,059,459 shares of the company’s stock, valued at $12,294,970.23. This trade represents a 2.06 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the stock in a transaction on Friday, September 27th. The shares were acquired at an average cost of $5.70 per share, with a total value of $57,000.00. Following the transaction, the chief executive officer now directly owns 10,000 shares in the company, valued at $57,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 420,965 shares of company stock worth $2,651,103 over the last three months. Company insiders own 13.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ENGN shares. Oppenheimer reiterated an “outperform” rating and set a $30.00 target price on shares of enGene in a research report on Tuesday, September 24th. Citizens Jmp raised enGene to a “strong-buy” rating in a report on Monday, November 18th. Morgan Stanley restated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 target price on shares of enGene in a research note on Friday, December 6th. Finally, Raymond James started coverage on enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price objective on the stock. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $30.38.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.